Luye Pharma Announces the Approval of Zepzelca® (Lurbinectedin for Injection) by China’s National Medical Products Administration for ...
Shanghai, December 3, 2024 - Luye Pharma Group today announced that the innovative drug Zepzelca® (lurbinectedin for injection) has been approved for marketing by China’s National Medical Products Administration (NMPA) through the priority review program. The drug is indicated ...
December 03,2024
Luye Pharma’s Ruoxinlin and Other Drugs Included on China’s 2024 National Reimbursement Drug List
Shanghai, November 28, 2024 – Luye Pharma Group today announced that several of its innovative products (including new indications) have been included in the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2024 ...
November 28,2024
11
2024-11
Luye Pharma’s Class 1 Innovative Antidepressant Targeting NET/DAT/GABAAR Approved for Clinical Trials in China
29
2024-08
Luye Pharma Announces 2024 Half Year Results
13
2024-08
Luye Pharma’s mRNA-based Therapeutic HPV Vaccine LY01620 Approved for Clinical Trials in China
05
2024-08
Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in China
28
2024-07
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder
23
2024-07
Luye Pharma Will Receive RMB 1.6 Billion Strategic Investment for Shenzhen Luye
04
2024-07
Luye Pharma’s Analgesic Drug Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) Approved for Marketing in China
27
2024-06
Luye Pharma’s Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI with No FDA-483 Issued
20
2024-06
Luye Pharma’s Jinyouping (Rotigotine Microspheres for Injection) Approved for Marketing in China
11
2024-06
Luye Pharma's Meibirui (Paliperidone Palmitate Injection) Approved for Marketing in China for Treating Schizophrenia
